However, copper chelators (such as TTM) or ATP7A inhibition can reverse this mechanism, selectively inducing cuproptosis in KRAS‐mutant cells and significantly suppressing tumor growth, representing a potential precision therapeutic strategy for KRAS‐mutant CRC [20]. Here, KRAS is linked to neoplasm.